Participants with weaker kidney function had a lower cognitive performance, regardless of age, sex, education, body mass index or cardio-vascular health. They also demonstrated brain atrophy ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal ...